Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 03 Jul 2026
Plasma CGRP levels were lower in adults with migraine vs healthy adults and did not vary by subtype, attack status, or preventive treatment use, questioning use of plasma CGRP as a migraine biomarker.
Read Full NewsAnjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.
Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.
Updated data from Breakfree-2 study showed that treatment with a single zola-cel infusion achieved NEDA-3 in highly active relapsing multiple sclerosis and led to mostly stable disability in progressive multiple sclerosis.
Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
At a NeurologyLive and Targeted Oncology Clinical Forum in Houston, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how incidental diagnosis and limited awareness of systemic therapy continue to delay care for patients with NF1-associated plexiform neurofibromas.
A secondary analysis of the BRIDGE-TNK trial found tenecteplase before thrombectomy improved functional outcomes in cardioembolic but not atherosclerotic stroke.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is recent advances in gene therapies.
1.
US Mental Health Treatment Rates Rise But Gaps Persist
2.
Virtual Help Doubles Cancer Patients’ Smoking Quit Rate
3.
An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.
4.
Could Burnout Become the Employer’s Responsibility?
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Intensive Care Strategies for Hyperacute Oncologic Emergencies
2.
Revolutionizing Cancer Treatment: ESMO's Updated Recommendations for Tumour NGS
3.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
4.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
5.
Oncology Team Communication Training for Clinical Learners
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
2.
Future of Hematology
3.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge